Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
To test for the first time the potential of a nicotinic agonist on cognitive symptoms in
people with mild cognitive impairment (MCI) in Parkinson's disease (PD), referred to as
PD-MCI.
Phase:
Phase 2
Details
Lead Sponsor:
King's College London
Collaborators:
AstraZeneca Helse Stavanger HF Innovative Medicines Initiative Masaryk University Michael J. Fox Foundation for Parkinson's Research Norges Parkinsonforbund, Norway Parkinsons Org UK Stichting Lygature University of Exeter